Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP323329.RAA6b0V4ebHY88ym0tXU25snQBZ4vB084VKzcdf46i79U130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP323329.RAA6b0V4ebHY88ym0tXU25snQBZ4vB084VKzcdf46i79U130_assertion type Assertion NP323329.RAA6b0V4ebHY88ym0tXU25snQBZ4vB084VKzcdf46i79U130_head.
- NP323329.RAA6b0V4ebHY88ym0tXU25snQBZ4vB084VKzcdf46i79U130_assertion description "[The impact of oral anticoagulant therapy, factor VIII level and quality of factor V-deficient plasma on three commercial methods for activated protein C resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP323329.RAA6b0V4ebHY88ym0tXU25snQBZ4vB084VKzcdf46i79U130_provenance.
- NP323329.RAA6b0V4ebHY88ym0tXU25snQBZ4vB084VKzcdf46i79U130_assertion evidence source_evidence_literature NP323329.RAA6b0V4ebHY88ym0tXU25snQBZ4vB084VKzcdf46i79U130_provenance.
- NP323329.RAA6b0V4ebHY88ym0tXU25snQBZ4vB084VKzcdf46i79U130_assertion SIO_000772 11414631 NP323329.RAA6b0V4ebHY88ym0tXU25snQBZ4vB084VKzcdf46i79U130_provenance.
- NP323329.RAA6b0V4ebHY88ym0tXU25snQBZ4vB084VKzcdf46i79U130_assertion wasDerivedFrom befree-20150227 NP323329.RAA6b0V4ebHY88ym0tXU25snQBZ4vB084VKzcdf46i79U130_provenance.
- NP323329.RAA6b0V4ebHY88ym0tXU25snQBZ4vB084VKzcdf46i79U130_assertion wasGeneratedBy ECO_0000203 NP323329.RAA6b0V4ebHY88ym0tXU25snQBZ4vB084VKzcdf46i79U130_provenance.